1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

KPTI
Karyopharm Therapeutics Inc.US flagNASDAQ Global Select
9.00
USD
-0.23
- -
203.97MMarket Cap
Karyopharm Therapeutics Inc.
KPTI
(NASDAQ Global Select)

Recent

price

9.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.23
0.97
0.96
0.11
0.11
0.06
0.52
8.01
9.9
22.5
41.84
28.78
19.17
17.88
13.36
10.57
Revenue per Share
-15.79
-24.33
-83.92
-36.51
-49.77
-43.8
-42.15
-47.11
-48.32
-40.87
-24.75
-30.28
-18.79
-9.41
-17.93
-13.63
Basic EPS, GAAP
-13.66
-23.93
-75.02
-26.15
-40.19
-33.76
-24.11
-42.64
-46.25
-33.39
-22.5
-27.42
-12.17
-15.71
-6.89
-4.13
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-19.5
-43.82
-154.67
-66.65
-108.03
-146.35
-161.88
-177.93
-211.44
-222.7
-235.04
-246.23
-195.25
-192.44
-160.9
-124.59
Book Value per Share
-19.37
-42.68
383.02
99.63
83.54
64.86
42.31
48.37
12.05
10.52
-15.89
-3.05
-17.88
-22.9
-26.79
-18.57
Tangible Book Value per Share
1
1
- -
2
2
3
3
4
4
5
5
5
8
8
11
14
Basic Weighted Avg Shares
- -
1
- -
- -
- -
- -
2
30
41
108
210
157
146
145
146
151
Sales/Revenue/Turnover
-6,783.55
-2,506.31
-8,772.61
-33,120.52
-47,630.4
-71,903.9
-8,133.21
-592.97
-462.85
-159
-46.84
-90.53
-88.71
-82.24
-62.1
-55.73
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
1
1
1
1
1
- -
- -
- -
Depreciation Expense
-10
-16
-34
-76
-118
-110
-129
-178
-200
-196
-124
-165
-143
-76
-196
-195
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-6,783.55
-2,505.99
-8,771.83
-33,090.39
-47,272.4
-71,153.9
-8,036.39
-588.1
-488.08
-181.59
-59.14
-105.23
-97.99
-52.62
-134.21
-129.02
Profit Margin (%)
5
-1
155
195
162
115
99
288
232
216
202
284
164
64
11
9
Working Capital
- -
- -
- -
- -
- -
- -
- -
103
123
129
178
176
174
170
212
198
LT Debt
-13
-28
155
207
198
162
129
183
50
51
-80
-17
-136
-186
-293
-266
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
14
22
33
LT Borrowings
177
206
192
LT Finance Leases
6
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
18
23
Market Capitalization
56
80
80

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
90
103
126
Cash, Cash Equivalents & STI
46
64
91
Accounts Receivable, Net
32
26
23
Inventories
4
4
4
Total Current Liabilities
87
92
117
Payables & Accruals
72
64
81
ST Debt
14
22
33
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.69%
95.02%
57.47%
Free Cash Flow
5.86%
-7.67%
-40.95%
Net Income, GAAP
15.19%
18.58%
156.52%
Sales/Revenue/Turnover
295.5%
12.39%
0.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33
43
39
31
145
2025
30
38
44
34
146
2026
35
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-4.85
2.95
-3.85
-3.67
-9.41
2025
-2.77
-4.32
-3.82
-5.71
-17.93
2026
-1.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PDS Biotechnology Corporation (PDSB)
TAKE Solutions Limited (TAKE.BO)
Pasithea Therapeutics Corp. (KTTAW)
Oncolytics Biotech Inc. (ONC.TO)
Hvsen Biotechnology Co., Ltd. (300871.SZ)
Apollomics, Inc. (APLM)
Business
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapies targeting nuclear export dysregulation for cancer and other diseases; its lead product, XPOVIO (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound, is approved by the FDA, European Commission, UK Medicines and Healthcare products Regulatory Agency, and Israeli Ministry of Health for multiple myeloma and diffuse large B-cell lymphoma in combination with other agents, and marketed as NEXPOVIO in Europe and the UK; the company advances a pipeline of SINE compounds including eltanexor and four clinical-stage drug candidates for hematologic malignancies and solid tumors such as endometrial cancer and myelofibrosis. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm maintains operations across the United States, Europe (with presence in Switzerland and Germany), Israel, and China, serving oncology patients through commercial activities, clinical trials, and patient support programs like KaryForward. Recent developments include significant refinancing transactions in May 2024 with HealthCare Royalty and convertible note holders, comprising a $100 million senior secured term loan and amended royalty agreements extending debt maturities to 2028-2029 to fund Phase 3 readouts expected in 2025; a collaboration with Bristol Myers Squibb to evaluate selinexor with mezigdomide in relapsed/refractory multiple myeloma; and Q3 2025 U.S. net product revenue of $32 million for XPOVIO, up 8.5% year-over-year, alongside ongoing inducement grants under its 2022 stock plan.

Company News

APIChat

  • prnewswire.com

    Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

  • seekingalpha.com

    Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript

  • gurufocus.com

    Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

  • prnewswire.com

    Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

  • prnewswire.com

    Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

  • prnewswire.com

    Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • prnewswire.com

    Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

  • prnewswire.com

    Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

  • zacks.com

    Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet

  • seekingalpha.com

    Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript

  • marketbeat.com

    Karyopharm Therapeutics Q1 Earnings Call Highlights

  • zacks.com

    Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates

  • prnewswire.com

    Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

  • prnewswire.com

    Karyopharm to Participate at Upcoming Investor Conferences

  • prnewswire.com

    Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

  • prnewswire.com

    Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

  • defenseworld.net

    Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving Average – What’s Next?

  • defenseworld.net

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Brokerages

  • defenseworld.net

    Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Rises By 20.9%

  • zacks.com

    Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?